Presentation on theme: "Transcatheter aortic valve replacement (tAVR) are emerging as a viable treatment option for severe aortic stenosis in patients with significant co-morbidities."— Presentation transcript:
Transcatheter aortic valve replacement (tAVR) are emerging as a viable treatment option for severe aortic stenosis in patients with significant co-morbidities. The purpose of this study is to determine the outcomes of high-risk patients with aortic stenosis and COPD. Between November 2007 and June 2012, 266 patients have been implanted with a TAVR at Penn as part of the PARTNER Trial. All patients undergo a complete comorbid workup, which includes echocardiogram, heart catheterization, PFTs, and a 6 minute walk test. 205 patients had no COPD *(STS definition: mild/no COPD) 61 patients had COPD *(STS definition: moderate to severe COPD) None Mild: FEV1 60% to 75% of predicted, and/or on chronic inhaled or oral bronchodilator therapy. Moderate: FEV1 50% to 59% of predicted, and/or on chronic steroid therapy aimed at lung disease. Severe: FEV1 50.
Both cohorts of patients with and without COPD have tolerated TAVR well without significant morbidity and improvement in NYHA class and 6 minute walks. 6 and 12 month echocardiographic and clinical data (including 6 minute walk tests and NYHA classifications) improvements demonstrate TAVR as a viable option for high-risk patients with severe aortic stenosis and COPD. Further investigation with longer follow up will be needed to target this population as we believe COPD is one of the greatest comorbidities that accompany aortic stenosis in these patients. No COPD (n=205) COPD (n= 61) P-Value 1 year Survival 80%92%0.284